Literature DB >> 19010083

Aortic balloon valvuloplasty--review and case series.

Richard J Jabbour1, Ron Dick, Anthony S Walton.   

Abstract

Aortic balloon valvuloplasty (BAV) was initially devised in the 1980s as an alternative procedure to the surgical treatment of aortic stenosis, with the theory behind it being both minimally invasive as well as having a lower complication rate [Hara H, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007 March;115(12):e334-8]. In practice however, the procedure was found to have a higher complication rate with only a modest haemodynamic improvement compared to the surgical approach. Most important of all it had an unacceptably high restenosis rate as a substitute for surgery [Otto CM, et al. 3-year outcome after balloon aortic balloon valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation 1994;89:642-50]. As a result, the procedure has fallen out of favour and has been abandoned at many health care facilities [Hara H, et al. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation 2007 March;115(12):e334-8]. This article will review the management of patients with severe aortic stenosis that are unsuitable to undergo surgery.

Entities:  

Mesh:

Year:  2008        PMID: 19010083     DOI: 10.1016/j.hlc.2008.09.009

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  2 in total

1.  Utility of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era.

Authors:  Luke Dawson; Alex Huang; Laura Selkrig; James A Shaw; Dion Stub; Antony Walton; Stephen J Duffy
Journal:  Open Heart       Date:  2020-04

2.  Direct transcatheter aortic valve implantation - one-year outcome of a case control study.

Authors:  Janusz Kochman; Lukasz Kołtowski; Zenon Huczek; Piotr Scisło; Leopold Bakoń; Radosław Wilimski; Bartosz Rymuza; Grzegorz Opolski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-11-17       Impact factor: 1.426

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.